Adage Capital Partners
FDMT icon

Adage Capital Partners’s 4D Molecular Therapeutics FDMT Stock Holding History

Adage Capital Partners’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.9M Buy
2,249,203
+644,047
+40% +$6.28M 0.04% 392
2026
Q1 		$14.9M Buy
1,605,156
+370,000
+30% +$3.22M 0.02% 578
2025
Q4 		$9.26M Buy
1,235,156
+1,060,156
+606% +$10.8M 0.01% 681
2025
Q3 		$1.52M Buy
+175,000
New +$1.05M ﹤0.01% 822

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners's FDMT Position: Q2 2026 in Review

Adage Capital Partners increased its 4D Molecular Therapeutics (FDMT) stake by 40% in Q2 2026, buying an estimated $6.28M and bringing the position to 2,249,203 shares worth $29.9M. The position accounts for 0.04% of the portfolio, ranked #392.

Adage Capital Partners first reported a position in FDMT in Q3 2025 and has held it in 4 quarters since. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Adage Capital Partners held 2,249,203 shares of 4D Molecular Therapeutics worth $29.9M as of Q2 2026.
  • Adage Capital Partners bought 644,047 4D Molecular Therapeutics shares in Q2 2026, an estimated $6.28M.
  • 4D Molecular Therapeutics made up 0.04% of Adage Capital Partners's portfolio in Q2 2026, its #392 holding.
  • Adage Capital Partners first reported a position in 4D Molecular Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.